Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

201929 citationsJournal Articlehybrid Open Access

Authors

Teresa Coelho

Aaron Yarlas · Optum (United States)

Márcia Waddington‐Cruz · Universidade Federal do Rio de Janeiro

Michelle K. White · Optum (United States)

Asia Sikora Kessler · Optum (United States)

Andrew Lovley · Optum (United States)

Michael Pollock · Akebia Therapeutics (United States)

Abstract

Patients with hATTR amyloidosis with polyneuropathy treated with inotersen showed preserved or improved QOL at 66 weeks compared to those who received placebo.

Topics & Keywords

Amyloidosis: Diagnosis, Treatment, Outcomes Parathyroid Disorders and Treatments Bipolar Disorder and Treatment

Publication Details

Published in: Journal of Neurology

Volume 267, Issue 4, pp. 1070-1079

DOI: 10.1007/s00415-019-09671-9

Field-Weighted Citation Impact: 1.46

Command Palette

Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis

Authors

Abstract

Topics & Keywords

Publication Details